Interpace Biosciences, Inc.
IDXG
$1.25
$0.00280.23%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2.10% | 17.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.10% | 17.22% | |||
| Cost of Revenue | 3.86% | 9.73% | |||
| Gross Profit | 1.01% | 22.40% | |||
| SG&A Expenses | 7.44% | -0.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.18% | 4.11% | |||
| Operating Income | -15.60% | 158.24% | |||
| Income Before Tax | -36.17% | 271.53% | |||
| Income Tax Expenses | 0.00% | 0.00% | |||
| Earnings from Continuing Operations | -36.24% | 273.43% | |||
| Earnings from Discontinued Operations | -10.81% | 28.85% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -37.92% | 340.60% | |||
| EBIT | -15.60% | 158.24% | |||
| EBITDA | -14.33% | 150.97% | |||
| EPS Basic | -38.16% | 339.96% | |||
| Normalized Basic EPS | -36.42% | 270.87% | |||
| EPS Diluted | -38.14% | 343.27% | |||
| Normalized Diluted EPS | -36.49% | 270.16% | |||
| Average Basic Shares Outstanding | 0.39% | 0.14% | |||
| Average Diluted Shares Outstanding | 0.50% | 0.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
